# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2010 Earnings Results

**Report date:** 2011-02-17 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2010

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Misses on EPS, Stock Down 0.08%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.17 | N/A | +47.20% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding future prospects. They highlighted the importance of their ongoing projects and investments.

**Key quotes:**

> Management expressed confidence in future product pipeline.

> They noted ongoing investments in research and development.

> There was an emphasis on long-term growth potential despite current losses.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report shows a significant surprise in EPS, but the stock reacted slightly down by 0.08%. The lack of revenue data and no guidance may have contributed to investor caution. Management's focus on long-term growth and product development suggests they are positioning for future success despite current challenges.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2010_